{"name":"Ascendis Pharma Bone Diseases A/S","slug":"ascendis-pharma-bone-diseases-a-s","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[],"pipeline":[],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMiuAFBVV95cUxPb1ZKbWVyMWtFMDVRVDNQOERVUWJqOEpwX1BOSkhWY3NTbmVIVm82NGQxdDU5elJQdWZ5UWttR3U3aVNvZU5nV2tPZ09LbXFILVhkZERnV2FKcTVQTGxaVUJmVERlN1Z2S3p5RS11VjdIelpXQlpPX21tVlpqZXNHOG1kZjFpdndNbUpUNlAzYW4waWhwTzZ1b3BySFRJZEd3M0xIUWhQYVEzcjNVNnJWQWJoLXpsNDFf?oc=5","date":"2026-04-06","type":"pipeline","source":"Stock Titan","summary":"First once-weekly growth treatment for achondroplasia reaches U.S. patients - Stock Titan","headline":"First once-weekly growth treatment for achondroplasia reaches U.S. patients","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMixgFBVV95cUxNd2E3dDZuTXpDajJPdExQMkgyQ25aaGJNUlM5S3RidUpabURoUkJPbUpLbWlHbFZiR05Jc0tFLW11OVoxSDBySFlRWmxCQTViRWtxQXBWOE45bVpYUXVubWFvaTAxQ0wyS1ZreTNBZ0k4OFRCazVmN1R1dHRkYngtYWJ6T1pOdEU4cVFIa3JSc292TGhvR0J2OFZsM29XUmFYQ1A2UUJrTW9uYnFKc251anZrdFdYSl9tX2FPNXh1bURSd3NxdkE?oc=5","date":"2026-03-16","type":"trial","source":"reuters.com","summary":"BioMarin stops mid-stage trials of bone disorder treatment - reuters.com","headline":"BioMarin stops mid-stage trials of bone disorder treatment","sentiment":"negative"},{"url":"https://news.google.com/rss/articles/CBMingFBVV95cUxNNHhZR19mQVpTMzNFOEQwSmF2eVpfYTFGTHd1MktUaHRHZW9yRW1IdDltSnl5dHZtci00WDZBTnB1QlJfbTJzLXhnazRxdnQxU1lUT0hoVlJOZW9ZQk9udVpxSmxjR0ZrTGtVRTdIdVd3dl9QMnVWWkR4NVc2TW02U0dNbnlzdlFnRXcxRVh4c21fZ1V4OVdVanRFT040dw?oc=5","date":"2026-03-02","type":"regulatory","source":"BioWorld News","summary":"Dwarfism drug gets FDA accelerated approval for Ascendis - BioWorld News","headline":"Dwarfism drug gets FDA accelerated approval for Ascendis","sentiment":"positive"},{"url":"https://news.google.com/rss/articles/CBMiuwFBVV95cUxPMjFpRUNjQU1BMFdjS1B3a3lVcHhZb2FFRm0yeUlrMVF3ZmxfNXhLeDAzbUc1U1M5U2VCT2FrNGt6QUVjYUViamllbGY0VVh3UmtGV3Q1TDctd0xSX2J2VDZPTmZZU0o1MnBJazNrdGplY1V1SDNKU3ZWd1J1aVFlMktGWG9XVVZLeUw4c3BqaTlEOWl5NEFMdy1wem1jTk1pTG5CVFNmYWtfYTBlYXJhV0E4Z0VPQ3FDTHlr?oc=5","date":"2026-02-27","type":"regulatory","source":"Stock Titan","summary":"FDA approves once-weekly growth drug for children with achondroplasia - Stock Titan","headline":"FDA approves once-weekly growth drug for children with achondroplasia","sentiment":"positive"},{"url":"https://news.google.com/rss/articles/CBMilgFBVV95cUxPUXNxN1M4Q20tSWxvdTNqQlFQT1lwN3l0blhVaURuTlJCZ2FabnZJeEtsWHVsN0FUdkxCSFJrX05Cckl6OExYVDdmeDViWWljeGppc3M5dzdzTE5JaTBTNmk3ZlBSSEl3TmFZQWVMT29EVE9pd2ZhcWp6SlNHMWd2aWJpcENfQVlMMXB5aEpGY3RsRllaQ1E?oc=5","date":"2026-02-06","type":"regulatory","source":"Financial Times","summary":"Pendopharm Announces the Approval of Yorvipath® (palopegteriparatide injection) for the Treatment of Chronic Hypoparathyroidism in Adults – Company Announcement - FT.com - Financial Times","headline":"Pendopharm Announces the Approval of Yorvipath® (palopegteriparatide injection) for the Treatment of Chronic Hypoparathy","sentiment":"positive"},{"url":"https://news.google.com/rss/articles/CBMiaEFVX3lxTE02VmhrZC00ZG04M19lanpyaXdpc1pWdDY4cnotY2RiaU1uR2dPdlBIdTZKVml5aFdVNlVNQWFkRVZCZXVLRjVBMGhiQ3Y5MzdCZTd3b3g5ZHRUUTJBaHBxMkZkY01aTHBw?oc=5","date":"2025-07-09","type":"regulatory","source":"MarketBeat","summary":"Ascendis Pharma A/S (ASND) FDA Approvals, PDUFA Dates & Drug Alerts 2026 - MarketBeat","headline":"Ascendis Pharma A/S (ASND) FDA Approvals, PDUFA Dates & Drug Alerts 2026","sentiment":"positive"},{"url":"https://news.google.com/rss/articles/CBMiuwFBVV95cUxNcnZ3Mi1adm9pdTBOZm1BVDlKRE01M1h1NFNDb1NKSmFDMUxoaVlMN2JwUzhBUEZhRmlOV2xDTnY4aUUtbkZ6eGlxcTZjWThrNUFGRS02aF83MkdvU3lvM19odHJJbDFUZ2o2TGNvMnNHd3FrTkhGeDh2V0VOaV9DT0VMNzNsdTlwd0IwM0tOWWpEUFVzck41SU11MU9lS3oxdTRhbFg1UVFsQWRmV3hlOFlxSEwxVTRtYTdV?oc=5","date":"2025-06-02","type":"regulatory","source":"Contemporary Pediatrics","summary":"FDA accepts navepegritide application to treat children with achondroplasia - Contemporary Pediatrics","headline":"FDA accepts navepegritide application to treat children with achondroplasia","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMitAFBVV95cUxOMzZWR01HeUFPdkFQSE1tZ2pqc2ZQbDFXZTdfQmRxaE9oQ0VmSWpGZkJ1SVJDRl92Z1pYMkp5dWQ1Sy04SU1DV0Y1TU5kMmFwNFZtYkxlYVdDY2l5Q1ItVnE4QmVsa2NfWkI1Xzg5OEF2SFM5N1NvY2YxTnAxZTA5WU9Td3lteldqaUJLS2hSelBubnZBSkNzTDBWdmNQSFl5bENSQW1FajlHbnpyU1lqM1Jlc1Y?oc=5","date":"2025-04-14","type":"deal","source":"Seeking Alpha","summary":"Ascendis Pharma: Rare Disease Player Is A Buy On Yorvipath Launch Trajectory (ASND) - Seeking Alpha","headline":"Ascendis Pharma: Rare Disease Player Is A Buy On Yorvipath Launch Trajectory (ASND)","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiogFBVV95cUxNbFhvQ0N0WW1mYjlWd3ExdWxKTm9sclpCUzF2WFJJZ21BMTg2NERBNFg2TTdldE92blhZV21BQmptXzhCUXRSMEFNa1NGVFVXeHViVGhUTVpHOXNUdkttLUlLWE5OUFdnSXRpN1A3NF90ZWQ1Y0VVMHp3QVFJWGJPdExFeDhqNzU1NkNGelNKdUpTV3RORjAyQ1M2SzI2TFFwbnc?oc=5","date":"2024-09-04","type":"pipeline","source":"Latham & Watkins LLP","summary":"Latham Watkins Advises Ascendis Pharma in US150 Million Royalty Financing - Latham & Watkins LLP","headline":"Latham Watkins Advises Ascendis Pharma in US150 Million Royalty Financing - Latham & Watkins LLP","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi6wFBVV95cUxPd3RKRV9SR0JjQWJnZVFtSWFtT3pGVUQzVk5zSGhDNjkwXzNDZXo5ZHluR3YtaFpBU1NsMkxEOHVFRXRhbm5idE9yNTRDY2owR01fVDhxWFpSM0VlaExzbzBYdnhkQ3BjNTIzSlpGRURUOERZZnRMeE9ZcTdVRHNYcEtTSW1OUXpPYUZTZ2VrbFZfQkxGbTN2dlVpdDl3TTJ0VXJObC1rdExRUXVHcmpvZ1QxVU42ZlhUd1J1dG1CbkU4aTJubmQ1Z29BMWRnMTdFajV3UWUwMnU4ZWFtTDByMHJFWjk4TllHSXlB?oc=5","date":"2024-09-03","type":"pipeline","source":"globenewswire.com","summary":"Ascendis Pharma and Royalty Pharma Enter into $150 Million Royalty Funding Agreement - globenewswire.com","headline":"Ascendis Pharma and Royalty Pharma Enter into $150 Million Royalty Funding Agreement","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi7gFBVV95cUxPQXQyTTY0b3p1NlVXckI3SGxuamppWHlfa1FMNGlmRG16WkxQdS02YTU3NzE1Y2FkLXNYMGpKNzBFc1lYb2lXSjVINlpuWlExY202aG1LamZHdEExTVFCNDJoZnhVcm1FZzdYeld2bmpCOUR2V0ZoRGpWS1Rac0dRWDl4LWtwdEx6cmpNRlZwT001V01tLXhNVGdITGt4SWlOdVRWTjV2QkhSRnVEc04yU2VGdUcwRW4tbGotSWR3T1VKOHRLYzlaeUF5SUVCMUxIRHJ0SEgyaFdnc2JnNlN0SHJRSUhKaGQtTlB3dDZn?oc=5","date":"2024-07-04","type":"pipeline","source":"Newswire Canada","summary":"Pendopharm signs exclusive distribution agreement with Ascendis Pharma A/S for TransCon™ PTH in Canada - Newswire Canada","headline":"Pendopharm signs exclusive distribution agreement with Ascendis Pharma A/S for TransCon™ PTH in Canada","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiakFVX3lxTFBMR2NhaE1Db3JVbUwzdEFSdXpMeEs3Ti1MdlQ0VFdkcklSc2Z3X1ZWOVFRNndKalVxWTVPYTlQbnlIRklLVGEzalBZdTY1T0NkM2pIdDdmUEIwYUF0aDdjUWZ0bF9mdnNKOHc?oc=5","date":"2022-10-21","type":"trial","source":"Wiley Online Library","summary":"Efficacy and Safety of Parathyroid Hormone Replacement With TransCon PTH in Hypoparathyroidism: 26-Week Results From the Phase 3 PaTHway Trial - Wiley Online Library","headline":"Efficacy and Safety of Parathyroid Hormone Replacement With TransCon PTH in Hypoparathyroidism: 26-Week Results From the","sentiment":"neutral"}],"patents":[],"drugCount":0,"phaseCounts":{},"enrichmentLevel":2,"visitCount":2,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}